110997-98-3

Upstream product

• 14737-89-4 3,4-dimethoxy-trans-cinnamic acid 
• 3929-47-3 3-(3,4-dimethoxyphenyl)-1-propanol 
• 3945-85-5 1-bromo-3-(3,4-dimethoxyphenyl)propane 
• 57293-20-6 <3-(3,4-dimethoxyphenyl)propyl>triphenylphosphonium bromide 
• 5600-62-4 4-(4-nitrophenyl)butanoic acid 
• 110997-82-5 1-(3,4-Dimethoxy-phenyl)-4-(4-nitro-phenyl)-butan-1-one 

Relevant academic research and scientific papers

Structural optimization of natural product nordihydroguaretic acid to discover novel analogues as AcrB inhibitors

Drug efflux pumps confer multidrug resistance to dangerous bacterial pathogens which makes these proteins promising drug targets. Herein, we present initial chemical optimization and structure-activity relationship (SAR) data around a previously described efflux pump inhibitor, nordihydroguaretic acid (NDGA). Four series of novel NDGA analogues that target Escherichia coli AcrB were designed, synthesized and evaluated for their ability to potentiate the activity of antibiotics, to inhibit AcrB-mediated substrate efflux and reduce off-target activity. Nine novel structures were identified that increased the efficacy of a panel of antibiotics, inhibited drug efflux and reduced permeabilization of the bacterial outer and inner membranes. Among them, WA7, WB11 and WD6 possessing broad-spectrum antimicrobial sensitization activity were identified as NDGA analogues with favorable properties as potential AcrB inhibitors, demonstrating moderate improvement in potency as compared to NDGA. In particular, WD6 was the most broadly active analogue improving the activity of all four classes of antibacterials tested.

Catechol based inhibitors of 15-lipoxygenase

A potent 15-lipoxygenase (15-LO) inhibitor, compound 6, was identified by mass screening the Parke-Davis compound portfolio. The active moiety of compound 6 was determined to be the catechol functionality. Additional analogs were prepared and analyzed for inhibitory activity against 5-, 12-, and 15-lipoxygenase.

N-SUBSTITUTED-2-HYDROXY-ALPHA-OXO-BENZENEACETAMIDES AND PHARMACEUTICAL COMPOSITIONS HAVING ACTIVITY AS MODULATORS OF THE ARACHIDONIC ACID CASCADE

The present invention relates to novel N-substituted 2-hydroxybenzamide and N-substituted 2-hydroxy-alpha-oxo-benezene acetamide compounds pharmaceutical compositions, and methods of use for therefore for the treatment of diseases in which products having lipoxygenase enzyme activity contribute to the pathological condition. Selected novel intermediates are also the present invention